6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
Small Vessel Cerebrovascular Disease
The First Affiliated Hospital with Nanjing Medical UniversitySmall moleculePhase 3Active
BBB
73/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 62/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Small Vessel Cerebrovascular Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Apixaban University of Edinburgh | Phase 3 | B |
Phenindione University of Edinburgh | Phase 3 | B |
Rivaroxaban University of Edinburgh | Phase 3 | B |
WARFARIN University of Edinburgh | Phase 3 | B |
Dabigatran University of Edinburgh | Phase 3 | B |
View all 10 →
Same molecule, other indications
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →